EA010588B1 - Порошковые лекарственные средства, содержащие соль тиотропия и ксинафоат салметерола - Google Patents

Порошковые лекарственные средства, содержащие соль тиотропия и ксинафоат салметерола Download PDF

Info

Publication number
EA010588B1
EA010588B1 EA200500902A EA200500902A EA010588B1 EA 010588 B1 EA010588 B1 EA 010588B1 EA 200500902 A EA200500902 A EA 200500902A EA 200500902 A EA200500902 A EA 200500902A EA 010588 B1 EA010588 B1 EA 010588B1
Authority
EA
Eurasian Patent Office
Prior art keywords
component
inhalation
tiotropium
salmeterol xinafoate
powder
Prior art date
Application number
EA200500902A
Other languages
English (en)
Russian (ru)
Other versions
EA200500902A1 (ru
Inventor
Хаген Грэбнер
Мареке Хартиг-Хаймель
Петер Зигер
Райнер Зойка
Михаэль Трунк
Михаэль Вальц
Original Assignee
Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32404034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA010588(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг filed Critical Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Publication of EA200500902A1 publication Critical patent/EA200500902A1/ru
Publication of EA010588B1 publication Critical patent/EA010588B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA200500902A 2002-12-20 2003-12-04 Порошковые лекарственные средства, содержащие соль тиотропия и ксинафоат салметерола EA010588B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10259912 2002-12-20
PCT/EP2003/013691 WO2004058233A1 (de) 2002-12-20 2003-12-04 Pulverförmige arzneimittel zur inhalation enthaltend ein tiotropiumsalz und salmeterolxinafoat

Publications (2)

Publication Number Publication Date
EA200500902A1 EA200500902A1 (ru) 2006-02-24
EA010588B1 true EA010588B1 (ru) 2008-10-30

Family

ID=32404034

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500902A EA010588B1 (ru) 2002-12-20 2003-12-04 Порошковые лекарственные средства, содержащие соль тиотропия и ксинафоат салметерола

Country Status (21)

Country Link
EP (1) EP1581198A1 (es)
JP (1) JP2006516135A (es)
KR (1) KR20050086930A (es)
CN (1) CN1728988B (es)
AU (1) AU2003288226B2 (es)
BR (1) BR0317443A (es)
CA (1) CA2510779A1 (es)
DE (1) DE10351663A1 (es)
EA (1) EA010588B1 (es)
EC (1) ECSP055855A (es)
FR (1) FR2848849B1 (es)
HR (1) HRP20050570A2 (es)
IT (1) ITMI20032473A1 (es)
MX (1) MXPA05006519A (es)
NO (1) NO20053548L (es)
NZ (1) NZ541303A (es)
PL (1) PL376231A1 (es)
RS (1) RS20050484A (es)
UA (1) UA83813C2 (es)
WO (1) WO2004058233A1 (es)
ZA (1) ZA200503692B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
CA2617897A1 (en) * 2005-08-06 2007-02-15 Boehringer Ingelheim International Gmbh Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
US8163913B2 (en) * 2005-12-19 2012-04-24 Sicor Inc. Forms of tiotropium bromide and processes for preparation thereof
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2810839A1 (en) * 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
DE102007036411A1 (de) 2007-07-20 2009-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator
UY31235A1 (es) * 2007-07-21 2009-03-02 Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
CN102971005A (zh) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 糖尿病治疗
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
KR101748796B1 (ko) * 2015-09-30 2017-06-19 한미약품 주식회사 활성성분의 전달량이 향상된 흡입용 캡슐제
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
BR112021009254A2 (pt) * 2018-11-13 2021-08-10 Cocrystal Pharma, Inc. formulações para produtos terapêuticos para influenza

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016031A1 (en) * 1992-02-11 1993-08-19 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
US5795594A (en) * 1993-07-01 1998-08-18 Glaxo Group Limited Salmeterol xinafoate with controlled particle size
WO2000069468A1 (de) * 1999-05-12 2000-11-23 Boehringer Ingelheim Pharma Kg NEUARTIGE ARZNEIMITTELKOMPOSITIONEN AUF DER BASIS VON ANTICHOLINERGISCH WIRKSAMEN VERBINDUNGEN UND β-MIMETIKA
WO2002030390A2 (de) * 2000-10-12 2002-04-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur herstellung von pulverformulierungen
WO2002038154A1 (de) * 2000-11-13 2002-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen auf der basis von tiotropiumsalzen und salzen des salmeterols
WO2002060532A1 (de) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Betamimetika enthaltende arzneimittelkompositionen mit geringeren nebenwirkungen
WO2003000241A2 (de) * 2001-06-23 2003-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen auf der basis von anticholinergika; corticosteroiden und betamimetika zur behandlung von entzündlichen und/oder obstruktiven atemwegserkrankungen
WO2003013633A1 (en) * 2001-08-09 2003-02-20 Glaxo Group Limited Inhalation device with a pharmaceutical composition
WO2003024452A1 (de) * 2001-09-14 2003-03-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittel zur inhalation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056974C (zh) * 1992-02-11 2000-10-04 格拉克索公司 适宜于微粒化的药物材料的制备方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016031A1 (en) * 1992-02-11 1993-08-19 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
US5795594A (en) * 1993-07-01 1998-08-18 Glaxo Group Limited Salmeterol xinafoate with controlled particle size
WO2000069468A1 (de) * 1999-05-12 2000-11-23 Boehringer Ingelheim Pharma Kg NEUARTIGE ARZNEIMITTELKOMPOSITIONEN AUF DER BASIS VON ANTICHOLINERGISCH WIRKSAMEN VERBINDUNGEN UND β-MIMETIKA
WO2002030390A2 (de) * 2000-10-12 2002-04-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur herstellung von pulverformulierungen
WO2002038154A1 (de) * 2000-11-13 2002-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen auf der basis von tiotropiumsalzen und salzen des salmeterols
WO2002060532A1 (de) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Betamimetika enthaltende arzneimittelkompositionen mit geringeren nebenwirkungen
WO2003000241A2 (de) * 2001-06-23 2003-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen auf der basis von anticholinergika; corticosteroiden und betamimetika zur behandlung von entzündlichen und/oder obstruktiven atemwegserkrankungen
WO2003013633A1 (en) * 2001-08-09 2003-02-20 Glaxo Group Limited Inhalation device with a pharmaceutical composition
WO2003024452A1 (de) * 2001-09-14 2003-03-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittel zur inhalation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS SHEKUNOV ET AL.: "Physical properties of supercritically-processed and micronized powders for respiratory drug delivery", XP002277844, Database accession no. 2003:353344, Zusammenfassung *
SHEKUNOV ET AL.: "Aerosolisation behaviour of micronised and supercritically processed powders", AEROSOL SCIENCE, Bd. 34, 2003, Seiten 553-568, XP002277843, das ganze Dokument Zusammenfassung, Seite 567, Absatz 2 *
SHEKUNOV ET AL.: "Physical properties of supercritically-processed and micronized powders for respiratory drug delivery", KONA, Bd. 20, 2002, Seiten 178-187, Zusammenfassung *

Also Published As

Publication number Publication date
ECSP055855A (es) 2005-11-22
BR0317443A (pt) 2005-11-16
CN1728988B (zh) 2010-04-28
AU2003288226A1 (en) 2004-07-22
MXPA05006519A (es) 2005-08-26
FR2848849B1 (fr) 2007-01-05
RS20050484A (en) 2007-11-15
DE10351663A1 (de) 2004-07-01
NZ541303A (en) 2008-11-28
WO2004058233A1 (de) 2004-07-15
JP2006516135A (ja) 2006-06-22
NO20053548L (no) 2005-09-02
HRP20050570A2 (en) 2006-07-31
UA83813C2 (ru) 2008-08-26
CA2510779A1 (en) 2004-07-15
AU2003288226B2 (en) 2010-01-07
ITMI20032473A1 (it) 2004-06-21
FR2848849A1 (fr) 2004-06-25
CN1728988A (zh) 2006-02-01
PL376231A1 (en) 2005-12-27
KR20050086930A (ko) 2005-08-30
ZA200503692B (en) 2006-10-25
EA200500902A1 (ru) 2006-02-24
EP1581198A1 (de) 2005-10-05

Similar Documents

Publication Publication Date Title
EA010588B1 (ru) Порошковые лекарственные средства, содержащие соль тиотропия и ксинафоат салметерола
US20070031347A1 (en) Powdered Medicaments Containing A Tiotropium Salt and Salmeterol Xinafoate
US8197845B2 (en) Encapsulated tiotropium containing powder formulation for inhalation
US7462367B2 (en) Anticholinergic powder formulations for inhalation
US7642268B2 (en) Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
KR100488644B1 (ko) 티오트로퓸을 함유하는 신규 흡입용 산제
AU2002344354B2 (en) Inhalation capsules
KR101021430B1 (ko) 미분화된 결정성 티오트로퓸 브로마이드
KR101066805B1 (ko) 티오트로퓸을 함유하는 흡입용 분말 제형
KR101007151B1 (ko) 흡입용 분말 제형
CA2531832C (en) Powdery formulations for inhalation, containing a novel anticholinergic agent
NZ540844A (en) Pulverulent formulation for inhalation containing tiotropium

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU